Mr. A. Barry Cohen

Axonyx Inc. (NASDAQ: AXYX) announced today the appointment of A. E. "Barry" Cohen to its Board of Directors.Barry Cohen is a retired Senior Vice President of Merck & Co., Inc. and President of Merck Sharp & Dohme International (MSDI).

Axonyx Inc.Chairman, Albert Angel, said, "Barry Cohen's distinguished career as a pharmaceutical industry leader and strategic thinker will serve us well as we continue to advance and expand our worldwide programs for the treatment and diagnosis of Alzheimer's Disease."
...
Mr. Cohen joined MSDI in New York in 1957 and moved to India in 1960 during the early development stages of the Merck subsidiary there.Subsequently, he played a key role in the development of Merck's international pharmaceutical business, becoming the first Managing Director for Pakistan in 1962 and Regional Director for South Asia in 1964.He became Regional Director for Northern Europe in 1967 and was elected MSDI's Vice President for Europe in 1969.

In 1974, Mr. Cohen was elected Executive Vice President of MSDI and became President of the Division in 1977.In 1982, he was named to serve concurrently as a corporate Senior Vice President.In this role, his responsibilities were significantly expanded to include oversight of worldwide strategic issues and the development and acquisition of new businesses outside the United States.

Mr. Cohen retired from Merck in 1992.He continues to be an active international business executive, serving as a director on the supervisory board of Akzo Nobel, NV and the boards of Teva Pharmaceutical Industries, Ltd., Neurobiological Technologies, Inc., Vasomedical, Inc., Pharmaceutical Products Development, Inc. and Smith Barney (Mutual Funds).

A.E. Barry CohenMr. Cohen served as a Senior Vice President of Merck and Company, Inc., the world's leading pharmaceutical company, and was the President of Merck, Sharp and Dome International.During his tenure at Merck, Mr. Cohen was the prime architect of the company's international business strategy and initiated the establishment of research facilities abroad.Mr. Cohen identified and established international markets of business development and marketing, which strategically positioned Merck as a powerful force and leader in the international pharmaceutical community.He established the Japanese pharmaceutical market for Merck which gave it access to the prestigious first tier of the Tokyo stock exchange.He was instrumental in effecting the ascendancy of Merck to the number one position among multinational pharmaceutical companies and the visionary who designed and implemented the acquisition of many of Merck's foreign subsidiaries.Mr. Cohen is currently Chairman of Chugai Pharma and serves on the Boards of Agouron Pharmaceuticals, Inc., Teva Pharmaceutical, Ind., Ltd., Akzo Nobel Nv, Immunomedics, Vasomedical, Inc., Neurobiological Technology, Inc., Vion Pharmaceutical, Inc., MeesPierson, Inc., The Population Council, and Smith Barney (Mutual Funds).

Plantation-based Viragen. (Amex: VRA) announced the election of A. E. Cohen and E. Donald Shapiro to its board of directors.
...
Cohen served as a senior VP of Merck & Co. for 10 years.He currently serves as a director of Akzo Corp. of the Netherlands, Teva Pharmaceutical Industries Ltd. in Israel, Gen-Probe USA, and Smith Barney -- Mutual Funds.Cohen is a trustee of the Population Council and is chairman of NTI, Vasomedical and NESS.

Plantation-based Viragen. (Amex: VRA) announced the election of A. E. Cohen and E. Donald Shapiro to its board of directors.
...
Cohen served as a senior VP of Merck & Co. for 10 years.He currently serves as a director of Akzo Corp. of the Netherlands, Teva Pharmaceutical Industries Ltd. in Israel, Gen-Probe USA, and Smith Barney -- Mutual Funds.Cohen is a trustee of the Population Council and is chairman of NTI, Vasomedical and NESS.

Mr. A. E. Barry Cohen served as the former President of the Merck Sharp & Dohme International Division and a Senior Vice President of Merck & Co. for a period of ten years.In his official capacities, Mr. Cohen executed Merck's worldwide strategic issues, the development and acquisition of new businesses and the manufacturing and marketing of human health products outside of the U.S.Mr. Cohen has played a key role in the development of Merck's international pharmaceutical business.He currently serves as a Director of Akzo Corporation (Netherlands), Teva Pharmaceutical Industries Ltd. (Israel), Gen-Probe USA., and Smith Barney - Mutual Funds.Mr. Cohen is a Trustee of the Population Council and is Chairman of NTI, Vasomedical, Inc. (NASDAQ) and NESS.

A.E. Barry Cohen, Director - Mr. Cohen served as the former President of the Merck Sharp & Dohme International Division and a Senior Vice President of Merck & Co. for a period of ten years.Mr. Cohen executed Merck's worldwide strategic issues, the development and acquisition of new businesses and themanufacturing and marketing of human health products outside the U.S.Mr. Cohen has played a key role in the development of Merck's international pharmaceutical business and currently serves as a Director for many major U.S. and foreign public corporations.

K. Frank Austen, M.D. | Bengt Samuelsson, M.D. | Sir John Vane, D.Sc., FRS | Nicolas G. Bazan, M.D., Ph.D. | Charles A. Dinarello, M.D. | Stephen M. Prescott, M.D. | Lanny J. Rosenwasser, M.D. | Daniel D. Von Hoff, M.D. | David K. Brophy, Ph.D. | Brad Barber, Ph.D. | Campbell R. Harvey, Ph.D. | Henry I. Miller, M.D. | David J. Crossen, Ph.D. | Marc J. Ostro, Ph.D. | Alex McPherson, M.D., Ph.D. | Ronald Meade | Antoine A. Noujaim, Ph.D. | Ariel Elia | Carlo Patrono, M.D. | Thierry Jean, Ph.D. | A.E. Barry Cohen | Jean-Claude Gonneau
...
A.E. Barry CohenMr. Cohen served as a Senior Vice President of Merck and Company, Inc., the world's leading pharmaceutical company, and was the President of Merck, Sharp and Dome International.During his tenure at Merck, Mr. Cohen was the prime architect of the company's international business strategy and initiated the establishment of research facilities abroad.Mr. Cohen identified and established international markets of business development and marketing, which strategically positioned Merck as a powerful force and leader in the international pharmaceutical community.He established the Japanese pharmaceutical market for Merck which gave it access to the prestigious first tier of the Tokyo stock exchange.He was instrumental in effecting the ascendancy of Merck to the number one position among multinational pharmaceutical companies and the visionary who designed and implemented the acquisition of many of Merck's foreign subsidiaries.Mr. Cohen is currently Chairman of Chugai Pharma and serves on the Boards of Agouron Pharmaceuticals, Inc., Teva Pharmaceutical, Ind., Ltd., Akzo Nobel Nv, Immunomedics, Vasomedical, Inc., Neurobiological Technology, Inc., Vion Pharmaceutical, Inc., MeesPierson, Inc., The Population Council, and Smith Barney (Mutual Funds).

K. Frank Austen, M.D. | Bengt Samuelsson, M.D. | Sir John Vane, D.Sc., FRS | Nicolas G. Bazan, M.D., Ph.D. | Charles A. Dinarello, M.D. | Stephen M. Prescott, M.D. | Lanny J. Rosenwasser, M.D. | Daniel D. Von Hoff, M.D. | David K. Brophy, Ph.D. | Brad Barber, Ph.D. | Campbell R. Harvey, Ph.D. | Henry I. Miller, M.D. | David J. Crossen, Ph.D. | Marc J. Ostro, Ph.D. | Alex McPherson, M.D., Ph.D. | Ronald Meade | Antoine A. Noujaim, Ph.D. | Ariel Elia | Carlo Patrono, M.D. | Thierry Jean, Ph.D. | A.E. Barry Cohen | Jean-Claude Gonneau | Gerard P. Joyce
...
A.E. Barry CohenMr. Cohen served as a Senior Vice President of Merck and Company, Inc., the world's leading pharmaceutical company, and was the President of Merck, Sharp and Dome International.During his tenure at Merck, Mr. Cohen was the prime architect of the company's international business strategy and initiated the establishment of research facilities abroad.Mr. Cohen identified and established international markets of business development and marketing, which strategically positioned Merck as a powerful force and leader in the international pharmaceutical community.He established the Japanese pharmaceutical market for Merck which gave it access to the prestigious first tier of the Tokyo stock exchange.He was instrumental in effecting the ascendancy of Merck to the number one position among multinational pharmaceutical companies and the visionary who designed and implemented the acquisition of many of Merck's foreign subsidiaries.Mr. Cohen is currently Chairman of Chugai Pharma and serves on the Boards of Agouron Pharmaceuticals, Inc., Teva Pharmaceutical, Ind., Ltd., Akzo Nobel Nv, Immunomedics, Vasomedical, Inc., Neurobiological Technology, Inc., Vion Pharmaceutical, Inc., MeesPierson, Inc., The Population Council, and Smith Barney (Mutual Funds).